Company Quick10K Filing
GT Biopharma
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 53 $13
10-Q 2019-11-14 Quarter: 2019-09-30
S-1 2019-09-13 Public Filing
10-Q 2019-08-14 Quarter: 2019-06-30
S-1 2019-06-21 Public Filing
10-Q 2019-05-15 Quarter: 2019-03-31
10-K 2019-03-29 Annual: 2018-12-31
10-Q 2018-11-14 Quarter: 2018-09-30
10-Q 2018-08-14 Quarter: 2018-06-30
10-Q 2018-05-15 Quarter: 2018-03-31
10-K 2018-03-01 Annual: 2017-12-31
10-Q 2017-11-14 Quarter: 2017-09-30
10-Q 2017-08-11 Quarter: 2017-06-30
10-Q 2017-04-28 Quarter: 2017-03-31
10-K 2017-03-31 Annual: 2016-12-31
10-Q 2016-11-14 Quarter: 2016-09-30
10-Q 2016-08-10 Quarter: 2016-06-30
10-Q 2016-05-13 Quarter: 2016-03-31
10-K 2016-03-30 Annual: 2015-12-31
10-Q 2015-11-13 Quarter: 2015-09-30
10-Q 2015-08-14 Quarter: 2015-06-30
10-Q 2015-05-14 Quarter: 2015-03-31
10-K 2015-03-31 Annual: 2014-12-31
10-Q 2015-01-08 Quarter: 2014-09-30
10-Q 2015-01-08 Quarter: 2014-06-30
10-Q 2015-01-08 Quarter: 2014-03-31
10-K 2015-01-08 Annual: 2014-03-31
10-Q 2014-12-17 Quarter: 2013-09-30
10-Q 2014-12-12 Quarter: 2013-06-30
10-Q 2014-12-10 Quarter: 2013-03-31
10-K 2014-11-18 Annual: 2012-12-31
10-Q 2012-11-21 Quarter: 2012-09-30
10-Q 2012-08-20 Quarter: 2012-06-30
10-Q 2012-05-21 Quarter: 2012-03-31
10-Q 2011-11-21 Quarter: 2011-09-30
10-Q 2011-08-22 Quarter: 2011-06-30
10-Q 2011-05-16 Quarter: 2011-03-31
10-K 2011-03-31 Annual: 2010-12-31
10-Q 2010-11-12 Quarter: 2010-09-30
10-Q 2010-08-16 Quarter: 2010-06-30
10-Q 2010-05-14 Quarter: 2010-03-31
10-K 2010-03-30 Annual: 2009-12-31
8-K 2019-09-19 Enter Agreement, Exhibits
8-K 2019-08-20 Enter Agreement, Sale of Shares, Exhibits
8-K 2019-05-22 Enter Agreement, Sale of Shares, Exhibits
8-K 2019-04-19 Sale of Shares
8-K 2019-04-04 Amend Bylaw, Exhibits
8-K 2019-03-20 Officers
8-K 2019-03-15 Officers
8-K 2019-02-04 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2019-01-07 Other Events, Exhibits
8-K 2019-01-07 Officers
8-K 2018-11-15 Earnings, Exhibits
8-K 2018-11-01 Other Events, Exhibits
8-K 2018-10-11 Officers
8-K 2018-10-09 Officers, Exhibits
8-K 2018-09-24 Enter Agreement, Sale of Shares, Exhibits
8-K 2018-09-07 Enter Agreement, Sale of Shares, Exhibits
8-K 2018-08-02 Enter Agreement, Sale of Shares, Exhibits
8-K 2018-07-02 Enter Agreement, Officers, Exhibits
8-K 2018-05-09 Officers, Exhibits
8-K 2018-04-23 Officers, Exhibits
8-K 2018-02-14 Officers, Exhibits
8-K 2018-01-22 Enter Agreement, Sale of Shares, Exhibits
8-K 2018-01-16 Officers, Exhibits

GT Biopharma Financials

GTBP Metrics, Comps, Filings

Annual | Quarterly

Business

We are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products based off our proprietary Tri-specific Killer Engager (TriKE), Tetra-specific Killer Engager (TetraKE) and bi-specific Antibody Drug Conjugate (ADC) technology platforms. Our TriKE and TetraKE platforms generate proprietary moieties designed to harness and enhance the cancer killing abilities of a patient’s own natural killer, or NK, cells. Once bound to an NK cell, our moieties are designed to enhance the NK cell and precisely direct it to one or more specifically-targeted proteins (tumor antigens) expressed on a specific type of cancer, ultimately resulting in the cancer cell’s death. TriKEs and TetraKEs are made up of recombinant fusion proteins, can be designed to target any number of tumor antigens on hematologic malignancies, sarcomas or solid tumors and do not require patient-specific customization. They are designed to be dosed in a common outpatient setting similar to modern antibody therapeutics and are expected to have reasonably low cost of goods. Our ADC platform generates product candidates that are bi-specific, ligand-directed single-chain fusion proteins that, we believe, represent the next generation of ADCs.

We are using our TriKE and TetraKE platforms with the intent to bring to market immuno-oncology products that can treat a range of hematologic malignancies, sarcoma and solid tumors. The platforms are scalable, and we are putting processes in place to be able to produce IND-ready moieties in a timely manner after a specific TriKE or TetraKE conceptual design. After conducting market and competitive research, specific moieties can then be advanced into the clinic on our own or through potential collaborations with larger companies. We are also evaluating, in conjunction with our Scientific Advisory Board, additional moieties designed to target different tumor antigens. We believe our TriKEs and TetraKEs may have the ability, if approved for marketing, to be used on a stand-alone basis, augment the current monoclonal antibody therapeutics, be used in conjunction with more traditional cancer therapy and potentially overcome certain limitations of current chimeric antigen receptor, or CAR-T, therapy.

We also believe our bi-specific, ligand-directed single-chain fusion proteins are examples of the next generation of ADCs. We believe GTB-1550 has certain properties that could result in competitive advantages over recently approved ADC products targeting leukemias and lymphomas and/or have utility in other niche populations. In a Phase 1 trial, of nine patients that achieved adequate blood levels, in two heavily pretreated patients a continuous partial remission (PR) and complete remission (CR) were observed. One of these patients, who had failed multiple previous treatment regimens, has been in remission since early 2015.


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Annual)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Destiny Media Technologies (DSNY) 13 0% 15.7 19% 3 1 4 0 1 1 12
XSport Global (TLLT) 13 36% -6.7 -349% 1 5 2 1 -3 -2 14
Rocky Mountain High Brands (RMHB) 13 8% -3.5 227,454,000% 0 0 -2 -4 13
Strategic Environmental & Energy Resources (SENR) 13 13% -9.9 -89% 3 8 7 1 -3 -1 13
Gilla (GLLA) 13 65% -3.1 -134% 4 13 4 3 -6 -4 14
FC Global Realty (FCRE) 13 122% 25.1 11% 4 5 0 0 0 0 12
Advanzeon (CHCR) 13 59% -12.3 -121% 2 29 0 0 -2 -2 24
nDivision (NDVN) 13 78% -15.9 146,140,300% 2 5 4 -1 -1 13
Black Box (BBOX) 13 27% 57.9 -21% 298 238 738 203 -63 2 93
GT Biopharma (GTBP) 13 -0.1 -962% 26 17 0 0 -247 -243 12
LifeApps Brands (LFAP) 13 100% -2.3 -1,669% 0 2 0 0 -5 -5 12
Vitalibis (VCBD) 13 43% -2.7 -1,081% 0 1 0 0 -5 -5 13
Inrad Optics (INRD) 12 26% 36.4 1% 7 5 11 3 0 0 12
ETF Managers Group Commodity Trust I (RISE) 12 15.0 5% 17 0 0 0 1 1 12
Rangeford Resources (RGFR) 12 -16.3 -156,832% 0 3 0 0 -1 -1 13
Tofutti Brands (TOFB) 12 29% -128.7 1% 5 2 12 4 0 -0 11
CannaPowder (CAPD) 12 -2.4 -1,041% 0 0 0 0 -5 -5 12
Mymetics (MYMX) 12 0% -4.9 -58% 8 57 1 0 -4 -2 12
Curaegis Technologies (CRGS) 12 -63% -4.6 -2,015% 0 11 0 -0 -6 -5 22
Integral Technologies (ITKG) 12 0% -2.9 -922% 1 5 1 0 -6 -4 12

Balance Sheet ($MM)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-03-312019-06-30
Cash0001001000
Accounts Receivable00
Inventory0000
PP&E00000000
Assets000100254252626
Accounts Payable1110123222
Long-Term Debt
Liabilities5763062193141617
Stockholders' Equity-5-6-6-30-62-1925211109
Income Statement ($MM)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-03-312019-06-30
Revenue0000000
Cost of Revenue0000000
Gross Profit-0000000
R&D00001119
SG&A33128813512
Tax00000000
Net Income-4-5-1-23-3321-143-259
Cash Flow ($MM)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-03-312019-06-30
Cash Operating-1-1-0-2-5-2-5-11
Cash Investing-00-0-00-0-0
Cash Financing110342610